These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 25068161)

  • 1. Disease stage determines the efficacy of treatment of a paediatric neurodegenerative disease.
    Hassiotis S; Beard H; Luck A; Trim PJ; King B; Snel MF; Hopwood JJ; Hemsley KM
    Eur J Neurosci; 2014 Jun; 39(12):2139-50. PubMed ID: 25068161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA.
    King B; Hassiotis S; Rozaklis T; Beard H; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM
    J Neurochem; 2016 May; 137(3):409-22. PubMed ID: 26762778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice.
    Beard H; Luck AJ; Hassiotis S; King B; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM
    Mol Genet Metab; 2015 May; 115(1):33-40. PubMed ID: 25795516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme replacement reduces neuropathology in MPS IIIA dogs.
    Crawley AC; Marshall N; Beard H; Hassiotis S; Walsh V; King B; Hucker N; Fuller M; Jolly RD; Hopwood JJ; Hemsley KM
    Neurobiol Dis; 2011 Aug; 43(2):422-34. PubMed ID: 21550404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Slow, continuous enzyme replacement via spinal CSF in dogs with the paediatric-onset neurodegenerative disease, MPS IIIA.
    King B; Marshall NR; Hassiotis S; Trim PJ; Tucker J; Hattersley K; Snel MF; Jolly RD; Hopwood JJ; Hemsley KM
    J Inherit Metab Dis; 2017 May; 40(3):443-453. PubMed ID: 27832416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of high dose, repeated intra-cerebrospinal fluid injection of sulphamidase on neuropathology in mucopolysaccharidosis type IIIA mice.
    Mader KM; Beard H; King BM; Hopwood JJ
    Genes Brain Behav; 2008 Oct; 7(7):740-53. PubMed ID: 18518922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose, continual enzyme delivery ameliorates some aspects of established brain disease in a mouse model of a childhood-onset neurodegenerative disorder.
    King B; Setford ML; Hassiotis S; Trim PJ; Duplock S; Tucker JN; Hattersley K; Snel MF; Hopwood JJ; Hemsley KM
    Exp Neurol; 2016 Apr; 278():11-21. PubMed ID: 26626972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease.
    Hemsley KM; Luck AJ; Crawley AC; Hassiotis S; Beard H; King B; Rozek T; Rozaklis T; Fuller M; Hopwood JJ
    Eur J Neurosci; 2009 Mar; 29(6):1197-214. PubMed ID: 19302155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice.
    Hemsley KM; King B; Hopwood JJ
    Mol Genet Metab; 2007 Mar; 90(3):313-28. PubMed ID: 17166757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of enzyme dose and dose-frequency in ameliorating substrate accumulation in MPS IIIA Huntaway dog brain.
    King B; Marshall N; Beard H; Hassiotis S; Trim PJ; Snel MF; Rozaklis T; Jolly RD; Hopwood JJ; Hemsley KM
    J Inherit Metab Dis; 2015 Mar; 38(2):341-50. PubMed ID: 25421091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice.
    Gliddon BL; Hopwood JJ
    Pediatr Res; 2004 Jul; 56(1):65-72. PubMed ID: 15128919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA.
    Rozaklis T; Beard H; Hassiotis S; Garcia AR; Tonini M; Luck A; Pan J; Lamsa JC; Hopwood JJ; Hemsley KM
    Exp Neurol; 2011 Jul; 230(1):123-30. PubMed ID: 21515264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse.
    Boado RJ; Lu JZ; Hui EK; Pardridge WM
    Mol Pharm; 2018 Feb; 15(2):602-608. PubMed ID: 29251941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA.
    Savas PS; Hemsley KM; Hopwood JJ
    Mol Genet Metab; 2004 Aug; 82(4):273-85. PubMed ID: 15308125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs--a proof of principle study.
    Hemsley KM; Norman EJ; Crawley AC; Auclair D; King B; Fuller M; Lang DL; Dean CJ; Jolly RD; Hopwood JJ
    Mol Genet Metab; 2009 Dec; 98(4):383-92. PubMed ID: 19699666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain Targeting in MPS-IIIA.
    Sorrentino NC; Fraldi A
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():630-8. PubMed ID: 27491210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of a heparan sulfate-derived disaccharide as a marker of accumulation in murine mucopolysaccharidosis type IIIA.
    King B; Savas P; Fuller M; Hopwood J; Hemsley K
    Mol Genet Metab; 2006 Feb; 87(2):107-12. PubMed ID: 16352454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel conditional Sgsh knockout mouse model recapitulates phenotypic and neuropathic deficits of Sanfilippo syndrome.
    Lau AA; King BM; Thorsen CL; Hassiotis S; Beard H; Trim PJ; Whyte LS; Tamang SJ; Duplock SK; Snel MF; Hopwood JJ; Hemsley KM
    J Inherit Metab Dis; 2017 Sep; 40(5):715-724. PubMed ID: 28451919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracisternal enzyme replacement therapy in lysosomal storage diseases: routes of absorption into brain.
    Jolly RD; Marshall NR; Perrott MR; Dittmer KE; Hemsley KM; Beard H
    Neuropathol Appl Neurobiol; 2011 Jun; 37(4):414-22. PubMed ID: 21175738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innate and adaptive immune activation in the brain of MPS IIIB mouse model.
    DiRosario J; Divers E; Wang C; Etter J; Charrier A; Jukkola P; Auer H; Best V; Newsom DL; McCarty DM; Fu H
    J Neurosci Res; 2009 Mar; 87(4):978-90. PubMed ID: 18951493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.